Navigation Links
ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
Date:12/1/2009

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that a new, recently completed preclinical study has affirmed the bioequivalence and comparable toxicity of ANX-514 and Taxotere® (docetaxel). Shin Poong Pharmaceuticals, ADVENTRX's partner for ANX-514 in South Korea, independently conducted the study and data analysis.

"Our independent confirmation of the bioequivalence and comparable overall safety of ANX-514 and Taxotere affirm our belief in both the emulsion platform technology underlying several ADVENTRX product candidates and its application to docetaxel," stated Mr. Byung Yong Kim, Executive Managing Director of Shin Poong Pharmaceuticals. "We intend next to conduct a separate clinical bioequivalence study of ANX-514 in South Korea and look forward to continuing to work with ADVENTRX toward the possible commercialization of ANX-514 in both the U.S. and South Korea."

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of the hypersensitivity reactions often associated with Taxotere.

In May 2009, ADVENTRX announced the results of a clinical bioequivalence study of ANX-514. ANX-514 was determined to have comparable overall safety as Taxotere, with no differences between treatment groups in severe toxicities. However, pharmacokinetic equivalence, the primary endpoint of the study, was not demonstrated based on benchmark regulatory standards. The study data revealed higher blood-levels of docetaxel during and immediately following infusion of the study drug (i.e., during the first hour of treatment) in patients receiving ANX-514 relative to those receiving Taxotere, but, at 10 minutes after the completion of infusion, docetaxel blood-levels were comparable and remained so through the end of the observation period. ADVENTRX is analyzing these short-term increased levels, which were the reason ANX-514 was outside benchmark regulatory standards for determining bioequivalence.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical results are not predictive of the success of subsequent clinical trials and that products will not perform as preclinical data suggests or as otherwise anticipated; the robustness of the preclinical study conducted by Shin Poong Pharmaceuticals and the validity of any conclusions drawn therefrom, including the risk that ADVENTRX did not independently verify the data or conclusions provided by Shin Poong Pharmaceuticals; the risk the FDA will determine that ANX-514 and Taxotere are not bioequivalent, including as a result of determining that increased docetaxel blood-levels during and immediately following infusion are clinically relevant; the risk that future studies of ANX-514, including those performed by Shin Poong Pharmaceuticals, will not demonstrate the bioequivalence of ANX-514 and Taxotere; the potential for regulatory authorities to require additional preclinical work and/or clinical activities to support regulatory filings, including prior to the submission or the approval of an NDA for ANX-514, which activities may increase the cost and timeline to NDA submission or approval and negatively impact ADVENTRX's ability to raise additional capital; the risk that ADVENTRX will be unable to raise sufficient additional capital to continue the development of ANX-514; the risk that ADVENTRX will be unable to raise sufficient additional capital on a timely basis to continue as a going concern; the risk that the performance of third parties on whom Shin Poong Pharmaceuticals relied to conduct its preclinical studies or evaluate the data, including contract laboratories and contract research organizations, may have been substandard, or they may have failed to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.

SOURCE ADVENTRX Pharmaceuticals, Inc.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26
2. ADVENTRX Pharmaceuticals Announces Closing of Financing
3. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
4. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
5. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
6. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
7. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
9. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
11. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):